A new two-drug combination of rifapentine and moxifloxacin can allow tuberculosis (TB) treatment to be taken once-weekly during the four-month continuation phase, Dr Amina Jindani of St George’s University Medical School, London, told the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta, on 6 March.
However, using the same drugs twice-weekly does not permit the total TB treatment course to be reduced from six months to four months, the study found.
The RIFAQUIN study compared two strategies for either reducing the length of the TB treatment course or reducing the total number of doses.
Source: Aidsmap